The overarching objective of the Integrated Molecular Technologies (IMT) Core is to promote and facilitate basic and translational Gl research by providing CURE: DDRCC investigators with access to state-of-the-art molecular technologies, including: 1) expertise, equipment and services for systems biology and high-throughput screening analyses; 2) expertise and equipment for peptide synthesis and protein/peptide analysis, and 3) expertise and viral vector cloning and production services to genetically engineer mammalian cell lines and primary cells for expression or inhibition of proteins and miRNAs both in vitro and in vivo. To fulfill this objective, the IMT personnel will pursue the following specific aims: 1) To provide CURE: DDRCC researchers with individually customized services that require highly specialized expertise and/or instrumentation at minimal cost. These services include (but are not limited to): a) providing or facilitating access to specialized protocols and/or expensive instrumentation for profiling changes in gene expression and cellular phenotype, high-throughput molecular screening of drug candidates, and analysis of peptide and protein expression and function; b) design and characterization of custom peptides and isolation and characterization of peptide/protein analysis; c) design, construction, and production of custom gene delivery vectors for expression of a specific peptide or protein of interest. 2) To serve as an educational and advisory resource for CURE: DDRCC researchers who wish to utilize state-of-the-art molecular technologies to further their own research studies. These services include (but are not limited to): a) training, consultation, and troubleshooting in techniques for design, implementation, and bioinformatic analysis of customized genomic and cytologic profiling assays and molecular screening assays; b) training, consultation, and troubleshooting in techniques for design, and use of custom peptides and quantitative analysis of protein expression and function, and c) training, consultation, and troubleshooting in techniques to genetically engineer mammalian cells in vitro and in vivo for functional protein expression or knockdown.

Public Health Relevance

By providing CURE: DDRCC researchers with highly specialized expertise and equipment for analysis and manipulation of gene and protein expression and high-throughput screening of therapeutic compounds, the Integrated Molecular Technologies Core supports our mission to investigate gastrointestinal biology and to develop new therapies for gastrointestinal disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK041301-30
Application #
9605774
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
2020-11-30
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
30
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Bonfiglio, Ferdinando; Zheng, Tenghao; Garcia-Etxebarria, Koldo et al. (2018) Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. Gastroenterology 155:168-179
Hoffman, Jill M; Sideri, Aristea; Ruiz, Jonathan J et al. (2018) Mesenteric Adipose-derived Stromal Cells From Crohn's Disease Patients Induce Protective Effects in Colonic Epithelial Cells and Mice With Colitis. Cell Mol Gastroenterol Hepatol 6:1-16
Kageyama, Shoichi; Nakamura, Kojiro; Fujii, Takehiro et al. (2018) Recombinant relaxin protects liver transplants from ischemia damage by hepatocyte glucocorticoid receptor: From bench-to-bedside. Hepatology 68:258-273
Wen, Yi; Scott, David R; Vagin, Olga et al. (2018) Measurement of Internal pH in Helicobacter pylori by Using Green Fluorescent Protein Fluorimetry. J Bacteriol 200:
Koon, Hon Wai; Wang, Jiani; Mussatto, Caroline C et al. (2018) Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-?B Activity. Antimicrob Agents Chemother 62:
Wang, Jiani; Ghali, Sally; Xu, Chunlan et al. (2018) Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites. Gastroenterology 154:1737-1750
Manatsathit, Wuttiporn; Khrucharoen, Usah; Jensen, Dennis M et al. (2018) Laparotomy and intraoperative enteroscopy for obscure gastrointestinal bleeding before and after the era of video capsule endoscopy and deep enteroscopy: A tertiary center experience. Am J Surg 215:603-609
Rankin, Carl Robert; Theodorou, Evangelos; Man Law, Ivy Ka et al. (2018) Identification of novel mRNAs and lncRNAs associated with mouse experimental colitis and human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 315:G722-G733
Park, S H; Naliboff, B D; Shih, W et al. (2018) Resilience is decreased in irritable bowel syndrome and associated with symptoms and cortisol response. Neurogastroenterol Motil 30:
Dong, Tien; Pisegna, Joseph (2018) Passing the ""Acid Test"": Do Proton Pump Inhibitors Affect the Composition of the Microbiome? Dig Dis Sci :

Showing the most recent 10 out of 1097 publications